Live virus vaccines provide significant protection against many detrimental human and animal diseases, but reversion to virulence by mutation and recombination has reduced appeal. Using severe acute respiratory syndrome coronavirus as a model, we engineered a different transcription regulatory circuit and isolated recombinant viruses. The transcription network allowed for efficient expression of the viral transcripts and proteins, and the recombinant viruses replicated to WT levels. Recombinant genomes were then constructed that contained mixtures of the WT and mutant regulatory circuits, reflecting recombinant viruses that might occur in nature. Although viable viruses could readily be isolated from WT and recombinant genomes containing homogeneous transcription circuits, chimeras that contained mixed regulatory networks were invariantly lethal, because viable chimeric viruses were not isolated. Mechanistically, mixed regulatory circuits promoted inefficient subgenomic transcription from inappropriate start sites, resulting in truncated ORFs and effectively minimize viral structural protein expression. Engineering regulatory transcription circuits of intercommunicating alleles successfully introduces genetic traps into a viral genome that are lethal in RNA recombinant progeny viruses.regulation ͉ systems biology ͉ vaccine design L ive virus vaccines represent a crucial intervention strategy that has been documented to improve the overall health of populations. Concerns regarding reversion to virulence by mutation and recombination, coupled with the associated challenges in developing these vaccines commercially, have diminished the appeal of live virus vaccines (1, 2). The dichotomy between the well known protective efficacy and the costs and risks of developing live virus vaccines has been recognized as a Grand Challenge in Global Health by the National Foundation for Infectious Diseases, which has called for new methods to prevent reversion or recombination repair.Severe acute respiratory syndrome coronavirus (SARS-CoV) emerged suddenly and spread worldwide in 2003, causing Ϸ800 deaths (3). Zoonotic SARS-CoV strains, common in farm animals and bats, dictate a need for continued surveillance and the development of efficacious vaccines (4, 5). SARS-CoV is a tractable system for innovative live virus vaccine design because the pathogen is highly virulent and replicates efficiently in animal models, and a robust reverse genetic system is available. Importantly, CoVs undergo RNA recombination events at high frequency, and recombination-mediated vaccine failures in animals are a problem (6).SARS-CoV contains a positive, single-stranded, Ϸ29,700-nt RNA genome bound by the nucleocapsid protein (N) and an envelope containing the S, ORF3a, E, and M structural proteins. The SARS-CoV genome contains nine ORFs, and ORF1 encodes the viral replicase proteins that are required for subgenomic and genome-length RNA synthesis (7). Downstream of ORF1 and interspaced among the structural genes are the unique SARS-CoV group-specif...